Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants

Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants

Abstract The highly selective, covalent Bruton’s tyrosine kinase inhibitor evobrutinib is under investigation for treatment of patients with multiple sclerosis (MS). Early clinical studies in healthy participants and patients with relapsing MS indicated that evobrutinib is well‐tolerated and effecti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Holger Scheible, Martin Dyroff, Annick Seithel‐Keuth, Eleanor Harrison‐Moench, Nadra Mammasse, Andreas Port, Angelika Bachmann, Jennifer Dong, Jan Jaap vanLier, William Tracewell, David Mitchell
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
Therapeutics. Pharmacology
RM1-950
Public aspects of medicine
RA1-1270
Acceso en línea:https://doaj.org/article/489421b638da46dbad0cbcea83c71c6e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/489421b638da46dbad0cbcea83c71c6e

Ejemplares similares